Pradip De, MS, PhD – Avera Cancer Institute Research – Sioux Falls, SD, 57105
Skip to Content
Alert IconEveryone, age 12 and older, is now eligible for the COVID-19 vaccine. Please visit our vaccination resources for more information.
Pradip De

Pradip De, PhD, MS

Research Scientist

Office Information

About Me

Pradip De, MS, PhD, is a Senior Scientist who is part of the Translational Oncology Laboratory at Avera Cancer Institute.

The laboratory’s mission includes five key elements:

  • Principal investigator-initiated research projects
  • Scientific interrogations of genomic alterations in patients at Avera Cancer Institute as well as the TRACK national rare-cancer trial program
  • Training and teaching of research-team members, including post-doctoral and graduate students
  • Departmental research based on recommendations of ACIs institutional review board
  • Extracurricular scholarly activity and academic exercise

Dr. De is the Research Scientist Lead in the Translational Oncology Laboratory and also serves as a member of the Clinical Advisory Council of Viecure as the Signal Transduction Pathway Consultant.

His Avera team includes Dr. Nandini Dey, Avera Research Scientist Lead and Laboratory Director; Jennifer Aske, research laboratory supervisor; Nischal Koirala, post-doctoral fellow; Xiaoqian Lin, research associate lead; and Adam Dale, research associate.

The major research interest of Dr. De involves scientific interrogation of the genomic alterations of tumors in patients who receive treatment at ACI. He also runs hypothesis-driven scientific projects to understand the mechanism of drug action in tumor cells and to test combinations of targeted drugs.

He also serves as an assistant professor of internal medicine at the University of South Dakota Sanford School of Medicine. He often mentors final-year medical students in this program.


With more than 50 published scholarly publications as well as decades in cancer research, Dr. De is also a prolific principal author of the scholarly presentation, book chapters, and much more. His scientific interrogation has been a part of several tumor boards both inside ACI and outside institutions.

Recently, he was invited to join the team that is developing the world-renowned TCF-001 TRACK (Target Rare Cancer Knowledge) study. TCF-001 TRACK (NCT 04504640) is a prospective clinical trial seeking to enroll 400 patients with rare cancers or cancer of unknown primary. The effort is led by TargetCancer Foundation (TCF), which has stood at the intersection of rare cancer patients, advocates, researchers and clinicians.

His scientific research was integral in more than 150 oral and posters in national and international symposiums and conferences.

Special Interests

Dr. De’s research focus is the investigation of signal processing in tumor cells with special reference to ER+ and HER2+ breast cancers.

With more than 25 years of experience as a signal transduction biologist, he seeks further to understand how phosphorylation and dephosphorization of cellular proteins coordinate signals in breast and gynecological cancers. His research looks at questions including:

  • The identification of novel biomarkers that are associated with response or resistance to cancer therapeutics.
  • Identification of “signaling hubs” as an enticing molecular target for subset-specific breast cancer therapy, one that has the potential to overcome conventional targeted therapy resistance, with the intent to translate these important findings into future clinical trials as well as laboratory-based research that serves to enhance patient care.
  • Study of the role of aberrantly activated signaling pathways, such as PI3K-AKT-mTOR and RAS-MAPK pathways, as potential therapeutic targets in subset-specific breast and OB/GYN cancers.
  • Development of multiple ex vivo models in solid tumors to investigate genomic predictors of anticancer drug sensitivity.



Calcutta University, Calcutta, India, Bachelor and Master of Science degrees

All India Institute of Medical Sciences, New Delhi, India, Doctorate


All India Institute of Medical Sciences, New Delhi, India, Post-Graduate Training

Indiana University-Purdue University, Indianapolis, Indiana, Post-Graduate Training

Emory University, Research-Track Instructor, Atlanta, Ga., Post-Graduate Training

Professional Memberships

  • American Association for Cancer Research (AACR)
  • American Society of Cancer Research (ASCO)

This directory contains information about the provider members of Independent Health Care Associates, Avera Health and all Avera entities, members of the Avera Medical Group, and employed select providers with Avera McKennan, Sioux Falls, SD and Avera Marshall, Marshall, MN and physicians with hospital privileges at Avera St. Luke's, Aberdeen, SD; Avera Sacred Heart, Yankton, SD; Avera Queen of Peace, Mitchell, SD; Avera St. Mary's, Pierre, SD.

Non-Avera web sites (e.g., Facebook, Twitter, etc.) linked to from this Web page, including any blogs or other personal, networking or social media Web sites, are not affiliated with, nor endorsed by any Avera facility. Opinions, views, and comments posted on these Web sites are not Avera's.  Avera assumes no legal liability or responsibility for the accuracy, completeness, or usefulness of any information, product, or process disclosed on these sites. The opinions of those posting comments, views or opinions on these sites do not necessarily state or reflect those of Avera and shall not be used for advertising or product endorsement purposes.

Live Better. Live Balanced. Avera.

Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.

© 2021 Avera Health, Sioux Falls, SD. All Rights Reserved.